Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mignani

Showing results (331-340 of 356) with videos related to

Pageof 36
Sort By:
Journal of Medicinal Chemistry|July 6, 2000
Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activityP Jimonet, Y Ribeill, G A Bohme, et al.
European Heart Journal. Cardiovascular Imaging|January 24, 2021
Trabecular complexity as an early marker of cardiac involvement in Fabry diseaseAntonia Camporeale, Francesco Moroni, Davide Lazzeroni, et al.
Scientific Reports|January 12, 2026
Zebra bodies recognition by artificial intelligence (ZEBRA): a computational tool for Fabry nephropathyGiorgio Cazzaniga, Maurizio Carbone, Raffaella Barretta, et al.
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of actionP Jimonet, G A Bohme, J Bouquerel, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|December 15, 2025
Prognostic role of myocardial storage, hypertrophy and inflammation/fibrosis in Fabry Cardiomyopathy: a new predictive score including T1 valuesAntonia Camporeale, Gianluigi Guida, Maurizio Pieroni, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2001
RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosisT Canton, G A Böhme, A Boireau, et al.
Cells|September 23, 2022
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway InhibitorsSilvia Codenotti, Daniela Zizioli, Luca Mignani, et al.
Journal of Medical Genetics|January 20, 2023
Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA studyAntonia Camporeale, Francesco Bandera, Maurizio Pieroni, et al.
Pageof 36

Showing results (331-340 of 356) with videos related to

Sort By:
Pageof 36
Journal of Medicinal Chemistry|July 6, 2000
Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activityP Jimonet, Y Ribeill, G A Bohme, et al.
European Heart Journal. Cardiovascular Imaging|January 24, 2021
Trabecular complexity as an early marker of cardiac involvement in Fabry diseaseAntonia Camporeale, Francesco Moroni, Davide Lazzeroni, et al.
Scientific Reports|January 12, 2026
Zebra bodies recognition by artificial intelligence (ZEBRA): a computational tool for Fabry nephropathyGiorgio Cazzaniga, Maurizio Carbone, Raffaella Barretta, et al.
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of actionP Jimonet, G A Bohme, J Bouquerel, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|December 15, 2025
Prognostic role of myocardial storage, hypertrophy and inflammation/fibrosis in Fabry Cardiomyopathy: a new predictive score including T1 valuesAntonia Camporeale, Gianluigi Guida, Maurizio Pieroni, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2001
RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosisT Canton, G A Böhme, A Boireau, et al.
Cells|September 23, 2022
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway InhibitorsSilvia Codenotti, Daniela Zizioli, Luca Mignani, et al.
Journal of Medical Genetics|January 20, 2023
Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA studyAntonia Camporeale, Francesco Bandera, Maurizio Pieroni, et al.
Pageof 36